Prospective evaluation of bone markers, parathormone and 1,25-(OH)2 vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz

[1]  B. Hollis.  Assessment and interpretation of circulating 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in the clinical environment. , 2012, Rheumatic diseases clinics of North America.

[2]  P. Narciso,et al.  A Randomized, Pilot Trial to Evaluate Glomerular Filtration Rate by Creatinine or Cystatin C in Naive HIV-Infected Patients After Tenofovir/Emtricitabine in Combination With Atazanavir/Ritonavir or Efavirenz , 2012, Journal of acquired immune deficiency syndromes.

[3]  M. Moroni,et al.  Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011. , 2011, The new microbiologica.

[4]  T. Brown,et al.  Bone Turnover, Osteoprotegerin/Rankl and Inflammation with Antiretroviral Initiation: Tenofovir versus Non-Tenofovir Regimens , 2011, Antiviral therapy.

[5]  P. Sax,et al.  Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. , 2011, The Journal of infectious diseases.

[6]  M. Stahl,et al.  Markers of Bone Turnover Are Elevated in Patients With Antiretroviral Treatment Independent of the Substance Used , 2011, Journal of acquired immune deficiency syndromes.

[7]  Joseph L. Goulet,et al.  Increased Risk of Fragility Fractures among HIV Infected Compared to Uninfected Male Veterans , 2011, PloS one.

[8]  M. Moroni,et al.  Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. , 2011, The new microbiologica.

[9]  C. Cooper,et al.  Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards , 2011, Osteoporosis International.

[10]  N. Watts,et al.  American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. , 2010, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[11]  H. Stellbrink,et al.  Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  Christopher H Schmid,et al.  Comparative performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study equations for estimating GFR levels above 60 mL/min/1.73 m2. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[13]  A. Copas,et al.  Tenofovir-Linked Hyperparathyroidism Is Independently Associated With the Presence of Vitamin D Deficiency , 2010, Journal of acquired immune deficiency syndromes.

[14]  B. Hollis.  Assessment and interpretation of circulating 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in the clinical environment. , 2010, Endocrinology and metabolism clinics of North America.

[15]  H. Bischoff-Ferrari,et al.  High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients , 2010, AIDS.

[16]  P. Tebas,et al.  Aging and HIV Infection: A Comparison Between Older HIV-Infected Persons and the General Population , 2010, HIV clinical trials.

[17]  M. Battegay,et al.  Virological and immunological responses to efavirenz or boosted lopinavir as first-line therapy for patients with HIV , 2009, Antiviral therapy.

[18]  P. Lips,et al.  First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir , 2009, AIDS.

[19]  M. Re,et al.  Metabolic bone disease in HIV infection , 2009, AIDS.

[20]  A. Levin,et al.  A Comparison of the Predictive Performance of Different Methods of Kidney Function Estimation in a Well-Characterized HIV-Infected Population , 2008, Nephron Clinical Practice.

[21]  M. Shlipak,et al.  Association of kidney function with inflammatory and procoagulant markers in a diverse cohort: A cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis (MESA) , 2008, BMC nephrology.

[22]  A. d’Arminio Monforte,et al.  Response to combination antiretroviral therapy: variation by age , 2008, AIDS.

[23]  C. Schmid,et al.  Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[24]  M. Díaz-Curiel,et al.  Evolution of bone mineral density in AIDS patients on treatment with zidovudine/lamivudine plus abacavir or lopinavir/ritonavir , 2008, HIV medicine.

[25]  S. Sidney,et al.  Cystatin C level as a marker of kidney function in human immunodeficiency virus infection: the FRAM study. , 2007, Archives of internal medicine.

[26]  N. Maalouf,et al.  CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications. , 2007, The Journal of clinical endocrinology and metabolism.

[27]  T. Brown,et al.  Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review , 2006, AIDS.

[28]  F. Sardanelli,et al.  Potential predictive factors of osteoporosis in HIV-positive subjects. , 2006, Bone.

[29]  C. Andrzejewski,et al.  BMC Infectious Diseases , 2006 .

[30]  G. Filler,et al.  Cystatin C as a marker of GFR--history, indications, and future research. , 2005, Clinical biochemistry.

[31]  J. Macías,et al.  Relationship Between Low Bone Mineral Density and Highly Active Antiretroviral Therapy Including Protease Inhibitors in HIV-Infected Patients , 2003, HIV clinical trials.

[32]  H. Rodbard,et al.  American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. , 2003, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[33]  D. Richman,et al.  Baseline Predictors of CD4 T‐Lymphocyte Recovery With Combination Antiretroviral Therapy , 2002, Journal of acquired immune deficiency syndromes.

[34]  J. J. Henning,et al.  Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.

[35]  J. Bollerslev,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1999 by The Endocrine Society Decreased Bone Formative and Enhanced Resorptive Markers in Human Immunodeficiency Virus Infection: Indication of Normalization of the Bone-Remode , 2022 .

[36]  S. Frøland,et al.  Severe deficiency of 1,25-dihydroxyvitamin D3 in human immunodeficiency virus infection: association with immunological hyperactivity and only minor changes in calcium homeostasis. , 1998, The Journal of clinical endocrinology and metabolism.

[37]  A. Goday,et al.  Bone remodelling in human immunodeficiency virus-1-infected patients. A histomorphometric study. , 1995, Bone.

[38]  M. Muñoz-Torres,et al.  Alterations in bone turnover in HIV-positive patients , 1993, Infection.

[39]  M. Holick,et al.  Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. , 1988, The Journal of clinical endocrinology and metabolism.

[40]  T. Westfall,et al.  ALTERATIONS IN THE , 1985 .

[41]  D. DuBois,et al.  A formula to estimate the approximate surface area if height and weight be known , 1989 .

[42]  D. D. Bois,et al.  CLINICAL CALORIMETRY: TENTH PAPER A FORMULA TO ESTIMATE THE APPROXIMATE SURFACE AREA IF HEIGHT AND WEIGHT BE KNOWN , 1916 .